Posted on

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

Appoints George Steinbrenner IV to its Board of Directors

CHICAGO, March 31, 2021 (GLOBE NEWSWIRE) — Wesana Health Inc. (“Wesana” or the “Company”), an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, today announced the successful closing of its approximately C$16.1 million oversubscribed private placement through a special purpose financing vehicle ahead of completing its go-public transaction. The round included existing investors Ambria Capital, LLC, as well as new investors JLS Fund, K2 & Associates, Sol Global, and George Steinbrenner IV.

“We are grateful to have the strong support from new and existing institutional investors as we close this oversubscribed financing. When we set out to establish Wesana, we were personally very motivated to bring alternative treatments to market for those suffering from traumatic brain injury. To our great pleasure we were able to find investors that are equally as motivated in not only our business model, but in the importance and unmet need for the innovative treatments we are developing. Enhancing our institutional ownership through this financing is a key step to providing us with the necessary capital to continue our clinical development,” said Daniel Carcillo, Co-Founder and CEO of Wesana Health.

Proceeds from the financing will be used primarily to fund the Company’s preclinical and clinical development of psychedelic-assisted therapy to treat traumatic brain injury (TBI). The financing will also allow for the Company to scale its senior leadership team as it works to deliver on key milestones.

Board of Directors Appointment

In addition to participating in the latest financing, George Steinbrenner IV has joined the Wesana Board of Directors. A life-long racing enthusiast, Steinbrenner IV has taken the approach of learning the business of motorsport from the ground up, beginning as an intern at Bryan Herta Rallysport in the Red Bull Global Rallycross Series ahead of forming Steinbrenner Racing in 2016. While a young team, Steinbrenner Racing and George Steinbrenner IV have achieved notable successes, including a 2019 win at Circuit of The Americas where Steinbrenner IV became the youngest-ever winning team owner in NTT INDYCAR Series history. Steinbrenner IV has continued expanding his business portfolio, launching driver talent agency Steinbrenner Management, business incubator Steinbrenner Business and the George4 Foundation to extend a family practice of philanthropy.

“Tremendous advancements in science have finally given us the tools to recognize and better understand the consequences of traumatic brain injuries, especially those that occur often in professional sports. It’s critical that we continue to push forward in this field to deliver innovative treatment options that can help people recover from the neurological and psychological damage associated with that trauma. In my field, it is disheartening to see athletes struggle following traumatic injury and seek out treatment after treatment that fails to improve their life and well-being. My team and I have done our due diligence and were blown away by the roadmap that Wesana has put forth to leverage new natural therapies for TBI. I am excited to join the Wesana Board and invest in the business to further support their growth strategy through continued research and clinical trials,” commented George Steinbrenner IV.

“I’m pleased to welcome George to the Board. Together, we will focus on pursuing integrated research opportunities between Wesana and the major sports leagues to eradicate the long-term ramifications of TBI. George’s large sports network, including close ties to NTT INDYCAR Series Racing and Major League Baseball, will provide us with access to and an ability to collaborate with these leagues and organizations that are at the forefront of assessing stringent concussion protocols. We look forward to leaning on George’s knowledge and experience as we explore various research synergies,” said Chad Bronstein, Executive Chairman of Wesana Health. “Further, I’m excited to see an impressive group of investors including George support Wesana in this financing.”

About Wesana Health
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

On February 2, 2021, Wesana Health entered into a definitive agreement with Debut Diamonds Inc. (“Debut”) to complete a business combination by way of a transaction (the “Transaction”) that will constitute a reverse takeover of Debut by Wesana Health. Upon closing of the transaction, Debut will change its name to Wesana Health Holdings Inc. and all of its directors and executive officers will resign and the board of directors and executive officers of Wesana Health Holdings Inc. will be comprised of the nominees of Wesana Health. Closing of the Transaction remains subject to satisfying various customary conditions precedent, including receipt of applicable regulatory and shareholder approvals.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: WesanaIR@kcsa.com
Phone: 212-896-1267

Media Contact:
Nick Opich / Brittany Tibaldi
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 347-487-6794

 

Primary Logo

Source: Wesana Health

Released March 31, 2021

Posted on

Delic Subsidiary Complex Biotech Discovery Ventures Ltd., Receives First Research Orders

After recently launching its Advanced Analytical Testing services, CBDV successfully receives orders through their new online payment platform 

VANCOUVER, BC, March 31, 2021 /PRNewswire/ –  Delic Holdings Inc. (the “Company”), (“DELIC”) (CSE: DELC) (OTCQB: DELCF), a psychedelic focused wellness company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV”), a licensed cannabis and psilocybin research laboratory specializing in chemical analytics, extraction optimization, and process design, has commercialized and received its first research orders for Advanced Analytical Testing services through CBDV’s new online payment platform.

Matt Stang, CEO and Co founder commented “CBDV has shown they have the foresight to see what is needed in industries before it is normal practice. We expect to see the same professional expertise they show in cannabis, in this new psychedelic industry. This is another milestone that shows our commitment to increasing shareholder value.”

CBDV recently launched its Advanced Analytical Testing service which offers a streamlined process that allows clients to conveniently order tests online and ship their samples directly to CBDV’s lab. Clients can choose from a wide range of tests that provide a comprehensive analysis on cannabis flower, concentrates, formulations, and vapor/smoke.

Chief Executive Officer, Dr. Markus Roggen, stated: “We saw the need for chemical analytics beyond compliant testing to enable producers to develop the next generation of cannabis products. Therefore, we wanted to bring the high precision tools we are using in our own research directly to Canadian producers. And to enable an efficient customer experience, while giving us a scalable platform, we put a lot of effort into this webstore.”

With access to facilities at the University of British Columbia, CBDV uses industry-leading instrumentation and chemical expertise to provide clients with a thorough analysis of their cannabis samples. Clients receive an in-depth and precise characterization of their materials throughout each stage of the product development process. The tests offered go beyond the basic compliance testing for product releases required by Health Canada. CBDV’s variety of tests include smoke analysis, NMR spectroscopy, X-ray crystallography, high resolution mass spectroscopy and many more that can be ordered directly on CBDV’s website.

For more information on the transaction between the Company and CBDV, please refer to the news release of the Company dated February 25, 2021.

About CBDV

Complex Biotech Discovery Ventures (CBDV), based at the University of British Columbia in Vancouver, BC, is a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Founded by award-winning chemists, Dr. Markus Roggen and UBC Professor Glenn Sammis, CBDV uses precision chemical analytics and metabolomics identification to advance the cannabis and psilocybin industries.

For media and service inquiries, please contact info@cbdvl.com. Learn more at www.cbdvl.com and follow us on LinkedIn: Complex Biotech Discovery Ventures and Instagram: @complexbiotech.

About DELIC

DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, closing of the transaction with CBDV (the “Transaction”), the growth and business of CBDV, potential earn out payments, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following:‎ the ability to consummate the Transaction; the ability to satisfy the conditions to closing of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the acquisition on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Posted on

BETTER PLANT REPORTS FISCAL YEAR-END FINANCIAL RESULTS

Vancouver, B.C. –  March 31, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”), a wellness company that develops and sells sustainable, plant-based products that are better for health and better for the earth,  reported its financial results for the year ended November 30, 2020. All amounts are in Canadian currency unless otherwise stated.

Complete, consolidated financial statements, along with related management discussion and analysis, can be found on SEDAR under the Company’s profile.

 

Key financial highlights of Fiscal 2020:

  • Annual revenues were $1,135,286, with gross profits of $737,623.
  • Product sales grew 422% from Q1 to Q4, averaging 141% growth per quarter.
  • Total revenue grew 407% from Q1 to Q4, averaging 136% growth per quarter.
  • Total assets grew by 36% from $3.4 million to $4.7 million.
  • Current ratio improved from 1.0 to 1.71.
  • No commercial debt at year end [excluding $60,000 of repayable Canadian business Emergency Business Account (CEBA)].
  • $5.6 million in financing raised through a shelf prospectus in Fiscal 2020.
  • Negative adjusted EBITDA was $5,958,136 for the year, a 44% reduction in negative adjusted EBITDA from prior year.
  • Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, excluding certain non-operating amounts.

 

 

Key corporate highlights:

Acquisition of Jusu Assets

On October 9, 2020, Better Plant completed the purchase of assets of Jusu Bars Inc., Jusu Body Inc. and Jusu CBD Inc., a Canadian wellness brand with products in the following categories:

  • plant-based beverages including cold-pressed juices and packaged juice cleanses with nut milks, smoothies, booster shots and other products in development;
  • plant-based personal care products, including skin care, hair care, body care and baby care; and,
  • plant-based all natural home cleaning products.

Better Plant also took over ownership and operation of Jusu Bar, a quick serve restaurant alternative in Victoria, British Columbia (“BC”), which serves up fresh, healthy and nutritious options with a focus on Jusu cold-pressed juices. Through its online eCommerce platform Jusubar.com, Better Plant offers direct to consumer sales of refrigerated juices with easy online ordering and convenient home and office delivery in select cities in Alberta and British Columbia.

Growth in Product Sales

During  the year, Better Plant achieved growth in product sales through ecommerce and retail channels.  Better Plant achieved 422% growth from Q1 to Q4, averaging 141% growth per quarter.   Its key product sales in fiscal 2020 were through direct to consumer Shopify enabled eCommerce platforms as well as distribution of plant-based products through retail stores.

The following image shows the growth in Better Plant product sales each quarter in Fiscal 2020. The following image shows the growth in Better Plant product sales each quarter in Fiscal 2020:

Initial Public Offering (“IPO”) of Subsidiary NeonMind

Subsequent to the year end, Better Plant’s partially owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) successfully completed its over subscribed IPO raising gross proceeds $4.6 million and initiated its listing on the Canadian Securities Exchange under the stock symbol of “NEON”.  Better Plant owns 33,313,500 shares in NeonMind (approximately 27% of its issued and outstanding shares), which are subject to a 3 year escrow agreement.

NeonMind is engaged in research and development of products to optimize human health and performance. NeonMind has two divisions, a consumer products division with a focus on mushroom infused products, and a pharmaceutical division engaged in drug development of psychedelic compounds.  In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate aims to use psilocybin to enhance a patient’s ability to adopt behaviours that cause weight loss through psychedelic-assisted cognitive therapy.  The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.

 

Financial Overview

For the year ended November 30, 2020, Better Plant’s total assets grew to $4.7 million from $3.4 million for the prior year.  The majority of the growth was contributed by the acquisition of the Jusu assets  which included plant-based product formulas, brand names, customer lists, and other related intellectual property. The asset acquisition added significant breadth to Better Plant’s plant-based product offering to include house cleaning products, baby products and cold-pressed juices.

Annual revenues were $1,135,286. Product sales were $266,299 including $130,287 achieved in the fourth quarter of the year with the inclusion of Jusu product sales. Better Plant anticipates continued growth in revenue for Jusu branded products going forward. During the past year, Better Plant focused on increasing product sales, especially in the region of North America, through eCommerce and retail distribution. Licensing is no longer Better Plant’s strategic focus and the company recognized licensing revenues of $415,000 in 2020 as compared to licensing revenues of $2,659,717 for the prior year. Better Plant also significantly reduced its consulting activities and reallocated resources to growing our own brands in fiscal 2020. Consulting revenue was $51,198 for the year ended November 30, 2020 as compared to $1,017,988 for the prior year. Negative adjusted EBITDA was $5,958,136 for the year, a 44% reduction in negative adjusted EBITDA from prior year. Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, excluding certain non-operating amounts. Net loss was $9,911,844 for the year, a 38% reduction in net loss in the prior year. Better Plant raised $5.6 million in financing through a shelf prospectus in fiscal 2020.

 

About Better Plant Sciences Inc.

Better Plant harnesses plant intelligence and leverages modern science to offer sustainable, plant-based products that are better for health and better for the earth. It makes and sells over 75 proprietary products, all made with 100% natural ingredients, under the brands Jusu, Urban Juve and Wright & Well.  It has a direct to consumer platform for refrigerated goods that offers easy online ordering and convenient home delivery in select cities in Alberta and BC. Better Plant operates Jusu Bar, a quick serve restaurant alternative in Victoria, BC, which serves up fresh, healthy and nutritious options with a focus on Jusu cold-pressed juices. Jusubar.com offers home delivery of refrigerated plant-based beverages consisting of cold-pressed juices and packaged juice cleanses. Through its Shopify enabled eCommerce sites getjusu.com and urbanjuve.com, Better Plant sells plant-based personal care products, including skin care, hair care, body care and baby care. Jusu also has a line of plant-based all natural home cleaning products that are sold to cleaning companies, retailers and sold directly to consumers.  Better Plant also offers operational, financial and other services to companies with businesses that align with Better Plant’s mission to help create a better world. Better Plant incubated NeonMind, which sells medicinal mushroom infused coffees and is developing drugs with psychedelic ingredients to treat obesity and to suppress appetite. Better Plant owns approximately 27.7% of NeonMind, which trades separately as a public company under the tickers CSE:NEON and OTC:NMDBF.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Core One Labs Completes Acquisition of Ketamine Infusions Centers of Texas Representing the Company’s First Psychedelics Clinic in the U.S. and Announces Fast Entry Inclusion in The Horizons Psychedelic ETF

Vancouver, British Columbia, Canada – March 31, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” or the “Company”), a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, is pleased to announce it has completed the acquisition (the “Transaction”) of Ketamine Infusions Centers of Texas Inc. (“KICT”), a U.S.-based health and wellness clinic that provides ketamine infusion therapy. The Transaction marks the first health and wellness operation for the Company is the United States.

The acquisition of KICT establishes a roster of patients in Texas for psychedelic-assisted psychotherapy utilizing the Company’s novel delivery system and API grade psilocybin, upon legalization.  Ketamine has long been used as an anesthetic during surgery to calm your mind and also to relieve the pain associated with certain procedures.  Most recently ketamine has been successfully used as a treatment for severe depression, chronic pain and migraines. A few of the benefits of ketamine as an alternative treatment measure are its rapid onset and its capability in decreasing the need and dependance on narcotic painkillers.  In a world where opioid and narcotic dependency is increasing at an exponential rate, Ketamine and other psychedelic treatments are proving to be an alternative solution to traditional treatments.

KICT was established to address the growing problem of depression and other mental health issues that continue to plague our society.  KICT’s goal is to be known as a center of excellence in the management of treatment-resistant depression. KICT strives to achieve this by providing unparalleled and individualized care based on the uniqueness of each of its patients.  KICT offers ketamine treatments to individuals suffering from depression, bipolar disorder, post-traumatic stress disorder and obsessive-compulsive disorder. KICT combines their medical expertise with their passion to help patients reach optimal levels of health and vitality through intravenous therapy services and wellness programs.

“Our acquisition of KICT represents Core One’s initial acquisition in the U.S. market and will enable us to implement our platform for psychedelic treatments as they are legalized.  Major depressive disorder affects almost 7% of adults in the U.S. (approximately 23 million adults).  Due to the COVID-19 pandemic, it is anticipated these numbers will increase substantially, and Core One, through its clinics, is poised to be at the forefront of addressing this potential,” stated Joel Shacker, CEO of the Company.

Transaction Structure

The Transaction was completed pursuant to a purchase agreement (the “Definitive Agreement”) among the Company, KICT and the unitholders of KICT (the “Vendors”) dated February 18, 2021. Pursuant to the Definitive Agreement, and in consideration for the acquisition of KICT, Core One issued 210,000 common shares (the “Consideration Shares”) to the Vendors.

The Consideration Shares are subject to a voluntary pooling arrangement and are subject to restrictions on resale until February 14, 2022.  In addition, the Consideration Shares are subject to a statutory hold period until July 30, 2021.

The Company is at arms-length from KICT and its shareholders. The Transaction neither constitutes a fundamental change, nor a change of business for the Company, nor has it resulted in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.

The Company also paid a finder’s fee of 21,000 common shares to a third-party who introduced the Transaction to the Company (the “Finder’s Shares”), as well as 2,100 common shares as an administration fee to each of two parties that provided administrative support in connection with the Transaction. The Finder’s Shares will be subject to a four-month hold from the date of issuance pursuant to the policies of the Canadian Securities Exchange.

Horizons Psychedelic Stock Index EFT

In other news the Company announces that it has been added on a fast entry basis to the first ever psychedelics exchanged traded fund (ETF) – the Horizons Psychedelic Stock Index ETF (the “Horizons Psychedelic ETF”), effective March 19, 2021.

The Horizons Psychedelic ETF, launched by Horizons ETFs Management (Canada) Inc., on January 26, 2021, trades under the ticker “PSYK” on the NEO Exchange, and is comprised of 23 publicly listed companies trading on various exchanges in the U.S. and Canada, having significant business activities in, or significant exposure to, the psychedelics industry.

PSYK will track the underlying North American Psychedelics Index, and German-based Solactive AG is the independent calculation agent for the index.  Additional details on PSYK, including how it is weighted and conditioned can be found on the Horizons ETFs website.

“Recent breakthroughs in research and increased support from the scientific and medical communities have led to a rapidly growing psychedelics as alternative treatment industry.  The Horizons Psychedelic ETF provides investors diversified exposure to the overall growth of the sector, which has gained tremendous interest from global investors and investment funds.  We are honored to be included in the PSYK ETF, and in the Company of some very well respected peers,” stated Joel Shacker. “The Company’s fast entry inclusion into the fund is a great milestone for us and signifies growing awareness and increasing confidence within the investment community about Core One Labs.  We look forward to growing our investor base and to the additional exposure we will witness as a result of this significant event.” stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release, including with respect to the business plans and operations of Core One and KICT, as well as the legalization of psychedelics in the United States and Canada. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry to Promote Marley Line of Functional & Psychedelic Mushroom Brand

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce the appointment of beer, wine and spirits brand marketing and communications expert, Stuart Kirby, as Vice President of Marketing & Communications as well as cannabis and hemp industries expert, Peter Holzworth, as Vice President of Business Development.

“I am delighted to welcome two very accomplished senior executives to key leadership positions with Silo Wellness,” stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “With a decorated career in the adult beverage industry marketing some of the most iconic brands in the space, I look forward to Stuart’s creativity in delivering and amplifying the Marley licensing agreement we have just recently announced. I am equally excited to welcome Peter, who has tremendous experience in the cannabis and hemp industries, and to having him replicate that success within the psychedelic and functional mushroom category.”

Kirby has more than twenty five years of experience with integrated strategic communications, brand public relations and consumer lifestyle marketing. He has overseen the marketing and communications functions for some of the most successful companies in their respective industries, such as the world’s leading supplier of wine, E & J Gallo, two leading global PR firms, Edelman and Hill & Knowlton as well as the world’s leading adult beverage supplier, DIAGEO.

Anchored to the belief that “with great opportunity comes an equal measure of responsibility,” Kirby has led numerous corporate social responsibility efforts from environmental sustainability plans and global responsible consumption initiatives to cause-related marketing campaigns and humanitarian relief operations partnering with non-profit entities such as Amnesty International, Surfrider Foundation, Pan-American Development Foundation, USAID and Habitat for Humanity.

“Throughout my career, I have had the great privilege of being entrusted as steward to some of the most iconic, lifestyle brands in the world. Marketing and publicizing the legacy of Bob Marley – a man, musician and mystic that I have long admired – may be one of the most exciting professional opportunities I have ever been responsible for,” commented Kirby. “I look forward to transforming this fast-moving industry with a brand that stands for ‘one love’ and translating that universal vision to positively impact the communities and cultures we partner with.”

A veteran of the capital markets, cannabis and hemp industries, Holzworth has specialized experience in mergers and acquisitions, big data, compliance and regulatory affairs as well as brand development. As Vice President of Business Development for Silo Wellness, he will introduce and scale the Marley-branded mushroom line to the world by establishing relationships with large-scale distributors in the nutraceutical, nutrition, smoke shop and big-box retail markets.

“It is my great pleasure to be entrusted with the awesome responsibility of taking one of the most beloved brand names in the world and applying my experience from the cannabis industry to scale this business exponentially in the immediate future,” exclaimed Holzworth. “I look very much forward to assisting Silo Wellness to lead and expand market accessibility, domestically and abroad, to the functional and psychedelics mushroom category. Given my international contacts, global market experience and new business development acumen, I am here to fast-track Silo’s industry leadership position and to scale the Marley brand globally in short order.”

Silo Wellness is also pleased to announce the appointment of Kenny Choi to the role of Corporate Secretary, effective immediately. The appointment of Mr. Choi follows the resignation of Mo Yang as the Corporate Secretary of Silo Wellness.

About Silo Wellness

The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness’ activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: www.SiloWellness.com

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. Other than statements of historical fact, all statements are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the appointment of officers of Silo Wellness and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

HAVN LIFE SCIENCES SIGNS LOI TO RESEARCH AND DEVELOP MEDICAL PSILOCYBIN WITH JAMAICAN COMPANY HYPHA WELLNESS

Havn Life believes operations can advance its business plan and potentially accelerate production of naturally-derived psilocybin for global medical research.

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, has entered into a letter of intent (LOI) with nutraceutical company Hypha Wellness Jamaica Psilocybin (HWJP) towards jointly researching and, subject to compliance with all applicable laws and regulations, producing standardized powdered homogenized psilocybin mushroom active pharmaceutical ingredient (API) products.

Headquartered in Kingston, HWJP is focused on the cultivation, extraction, and manufacturing of nutraceuticals. They are uniquely positioned to explore and optimise the therapeutic and commercial potentials of psilocybin and other fungi for local and international markets. This collaboration is expected to further Havn Life’s goal of developing a supply chain for regulated production of medical psilocybin. Working with Veterans and thought leaders in the military, Havn Life is developing innovative formulations to support future clinical trials addressing PTSD recovery and other trauma related disorders, empowering people to connect to their potential and thrive.

Havn Life also notes that it is developing a production facility in Jamaica to produce psychedelic mushroom API. The Company is also actively engaged in pursuing additional opportunities to collaborate with the scientific and business communities in Jamaica.

Havn Life believes that setting up operations in Jamaica will advance the Company’s ability to optimize standardized quality controlled production methods for naturally-derived psilocybin, accelerating its overall business plan.  Collaborating with HWJP also brings local knowledge and insight to the Company’s operation, potentially paving the way towards the development of functional standards across the industry.

“Growing regulated psilocybin mushrooms for medical research is a very complex process. Our Jamaican collaborations are expected to allow us to optimize and refine our processes faster than we could elsewhere. Most importantly, they’re expected to better facilitate Havn Life’s commitment to helping patients, specifically those participating in observational studies in Jamaica,” says Dr. Ivan Casselman, Chief Psychedelic Officer of Havn Life. “Havn Life’s work in Jamaica is aimed at furthering our mandate of supplying safe, quality controlled, psilocybin medicine to researchers and patients around the globe. We want to supply as many researchers as we can with naturally derived compounds and this partnership will bring us one step closer to our goal of building an international psychedelic supply chain framework.”

For HWJP, the partnership represents a major milestone in its work toward facilitating industry growth and building an innovative framework for creating and distributing Jamaican nutraceuticals and pharmaceuticals across the island and around the world.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

Posted on

Psilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using Brain Scientific Mapping Neurocap

TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness”) (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces and Ehave, Inc. (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to collaborate on a data- study in coordination with select volunteer participants of Silo Wellness’ Jamaican psilocybin-facilitated wellness retreats.

The study will focus on studying transitions in and out of the altered state of consciousness caused by psychedelic molecules and offer a safe and powerful means of advancing knowledge on the neurobiology of non-ordinary conscious states. Advancing the understanding of the neurobiological underpinnings of immersive states of consciousness could ultimately help researchers find better treatment approaches for diseases such as chronic pain, depression (major and persistent), bipolar disorder, general anxiety, ADHD and Schizophrenia. Ehave’s proprietary dashboard will be used to collect and sort data from the brain mapping study.

Ehave will integrate Brain Scientific’s NeuroCap and NeuroEEG to acquire data from participants in real time. The study with Silo Wellness will allow Ehave to deploy NeuroCap and NeuroEEG in order to capture the data around the electrophysiological changes in brain pre-, mid-, and post-psychedelic drug administration. This will allow researchers to measure the efficacy of psychedelic molecules on various mental health indications that might open new doorways for psychedelic research and development of molecules to address various mental health disorders with great precision and efficiency.

Ehave CEO, Ben Kaplan said, “Brain mapping reveals which areas of the brain are not working the way they should, as well as how those areas are affected by external factors.” Mr. Kaplan continued, “The brain mapping process will allow us to see inside the brain to identify the effects of psilocybin molecules and its derivatives on brainwaves. From the data we receive from the brain map, a report will be generated for each patient that shows the areas affected.”

“Silo Wellness is delighted to collaborate on discovering innovative methods to assist in delivering the most optimal experience of wellness retreat participants through the screening of psychoactivity, which may enable us to learn even more about therapeutic dosing of psilocybin products,” commented Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “Scientific approaches such as this align with our ongoing commitment to leverage technology, applications and formats, such as our patent-pending psilocybin nasal spray, to both destigmatize and transform the psychedelics landscape.”

The study will assimilate data of select volunteers of Jamaican psilocybin retreat participants by measuring brain activity for a duration of 15-30 minutes before the administration of psilocybin and its derivatives. The participant shall wear an EEG neurocap during the entire process of the study and for 15-30 minutes after the administration of the psilocybin and its derivatives.

“This study will be conducted using EEG devices to measure the brain activity before, during, and after administration of psilocybin and its derivatives. To conduct the test, we place a comfortable cap on the individual’s head. The cap contains sensors that measure brainwaves of various frequencies. This is an entirely non-invasive reading of the brain’s activity and frequency patterns,” said Alfred Farrington II, Chief Information Officer of Ehave.

Dr. Manideep Gopishetty, Medical Advisor for Ehave said, “Understanding the effects psychedelics have on human brain activity and how it’s impacting the consciousness could be a key to building a more sustainable and effective treatment protocol for various mental health disorders.”

“This is part of Silo Wellness’s commitment to the advancing psychedelic compounds in familiar delivery modalities,” stated pharmacologist Dr. Parag Bhatt, Silo medical advisor and co-inventor of the nasal spray. “We are using this endeavor to evaluate the feasibility of an advanced tool to potentially use in a future study to prevent hyper-therapeutic dosing of psychedelics in line with our psilocybin nasal spray and other metered-dosing patent application claims.”

Ehave will be responsible for collecting and sorting data from the brain mapping study with its Ehave Dashboard. Ehave will also be responsible for designing the protocol for the brain mapping study, finalizing the principal investigator and medical monitor, providing the EEG equipment, as well as training the ground staff in Jamaica to handle the EEG equipment.

In addition to developing and facilitating the psilocybin-assisted wellness retreat agenda, Silo Wellness will be responsible for procuring the retreat sites for the brain mapping study to take place in Jamaica. Silo Wellness will also be responsible for facilitating the administration of psilocybin and its derivatives in natural variants.

Silo Wellness Grant of Incentive Stock Options

Silo Wellness announces that it has granted 5,500,000 stock options to certain directors, officers and consultants of Silo Wellness pursuant to Silo Wellness’ stock option plan. The stock options vest immediately and may be exercised at a price of $0.25 per common share for a period of five years from the date of issue. This grant of options is subject to the approval of the Canadian Securities Exchange.

About Silo Wellness

The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since inception, Silo Wellness’ activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities. Additional information on Silo Wellness can be found on the Company’s website at: www.silowellness.com.

For further information, please contact: www.SiloWellness.com

Media Relations:
Stuart Kirby, VP of Marketing and Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@silowellness.com

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals, The Hospital for Sick Children in Ontario. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health by enabling them to carry their medical records with them wherever they go. As a result of a strategic partnership with BurstIQ to further develop the blockchain capabilities of its platform, the Ehave Dashboard has the ability to segment data on-chain, which will allow developers, clinicians, researchers, doctors, hospitals, universities and, ultimately, prescribers of Psychedelic therapy, to provide life-changing solutions to patients. BurstIQ is a HIPAA and GDPR compliant global data platform, and the industry’s only Big Data blockchain that keeps data on chain and safe in the cloud.

Contact for 20/20 Global and Ehave

Media Inquiries: Gabe Rodriguez
Email: Gabe@Ehave.com

Investor Relations:

Email: Ir@Ehave.com
Phone: (623) 261-9046

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the brain mapping study partnership with Ehave, the grant of incentive stock options and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

All information contained in this news release with respect to Ehave and Silo Wellness was supplied by each party respectively for inclusion herein and each party has relied on the accuracy of such information without independent verification.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Delic Appoints John Coleman as Vice President of Business Development

VANCOUVER, BC, March 16, 2021 /PRNewswire/ – Delic Holdings. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of John Coleman, PhD, former President of Anandia Labs, as Vice President of Business Development.

Matt Stang commented “We are very fortunate to have John join our team. His pedigree between his corporate and scientific expertise is second to none. Having John join as our VP of Business Development shows our commitment to bringing top tier professionals to our team and having leaders in each pillar of our growing business.”

John has a wide-ranging scientific and business background. In 2013, he co-founded Anandia Labs, a cannabis biotech company focused on genetics and analytics, and helped grow it to approximately 90 staff before Anandia was purchased in 2018 by Aurora Cannabis.

Prior to Anandia, John was the Department Head of the Centre for Drug Research and Development’s (CDRD, now adMare BioInnovations) Project Search and Evaluation Division (2007-2015) where he was responsible for establishing and managing partnerships with academic institutions and identifying projects with therapeutic and commercial potential.

Before CDRD, he held various positions at Inflazyme Pharmaceuticals Ltd. (2000-2007), a Vancouver-based biotechnology company specializing in the development of treatments for respiratory and inflammatory diseases. Prior to Inflazyme, John led the natural products group at Ocean Nutrition Canada (1999-2000) after having completed a postdoctoral fellowship in the Marine Natural Products Chemistry group at the National Research Council in Halifax, Nova Scotia (1998-1999).

John holds a BSc (Honours) from Bishop’s University (1992) and a PhD from the University of British Columbia (1997). His PhD research on naturally-derived anticancer compounds produced the drug candidate HTI-286 that was licensed to Wyeth, where it progressed to Phase II clinical trials.

John commented “I am excited to join the excellent team that Matt and Jackie Stang founded and are building at DELIC to continue unlocking the potential of ketamine and psilocybin, and the potentially addition of other psychedelics, to address psychiatric, behavioral and mental health disorders plaguing our society. DELIC is positioning itself to be a leader in both the educational and scientific sides of the burgeoning psychedelic industry.”

The Company’s Board of Directors have approved the granting of 250,000 incentive stock options to Dr. Coleman at an exercise price of $0.55 as of the closing of business on March 9, 2021. The stock options are exercisable for a period of 3 years in accordance with the terms of the Company’s Incentive Stock Option plan.

About DELIC
DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Posted on

Silo Wellness to market ‘Marley Mushrooms’

KINGSTON, Jamaica — International firm, Silo Wellness Inc, has announced that it has entered into a multi-year licencing agreement with the family of legendary Jamaican musician, Bob Marley, to market psychedelic mushrooms.

According to a release from Silo, a wellness company engaged in the psychedelics and functional mushroom marketplaces, the agreement covers the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms.

 

Silo Wellness said it is pleased to announce the multi-year licence agreement with the family, which had been in negotiation for some time.

 

“These are transformative times in which we are living. Our family seeks to use our platform to help facilitate positive change. Mushrooms have been used for centuries, and we believe they offer a natural pathway for healing and positivity,” commented Cedella Marley, daughter of Rita and Bob Marley.

 

The licensing agreement contemplates the development of a stand-alone Marley brand portfolio of functional and psychedelic micro-dosing mushroom products, formats, devices and promotional items.

 

To honour Marley’s legacy in Jamaica, Silo Wellness says it has pledged a percentage of product sales to be contributed towards a charitable organization, which is to be mutually agreed upon between the Marley family and Silo, and the details of which will be made public in a future announcement.

 

“We are incredibly excited to strike a long-term licensing agreement with the most iconic brand to ever emerge from Jamaica,” stated Douglas K Gordon, Chief Executive Officer of Silo Wellness.

The licensing agreement contemplates the development of a stand-alone Marley brand portfolio of functional and psychedelic micro-dosing mushroom products, formats, devices and promotional items.

 

Balford Henry

 

 

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at https://bit.ly/epaper-login

Posted on

Family of Bob Marley and Silo Wellness Collaborate to Debut Exclusive Worldwide Functional & Psychedelic Mushroom Brand

MONTEGO BAY, Jamaica, March 11, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce it has entered into a multi-year license agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms.

“Our family is happy to collaborate with Silo Wellness to create the first ever global mushroom brand,” commented family matriarch Rita Marley. “When Bob and I were young we followed a strict, natural diet and we would include medicinal mushrooms. Mushrooms fit with our vision of a world transformed for good through natural products.”

“These are transformative times in which we are living. Our family seeks to use our platform to help facilitate positive change. Mushrooms have been used for centuries, and we believe they offer a natural pathway for healing and positivity,” stated Cedella Marley, daughter of Rita and Bob Marley.

At the epicenter of the psychedelic mushroom movement, Jamaica is the only country in the world where psilocybin is not illegal to grow, extract and sell, thereby positioning the island nation to directly benefit from wellness tourism as well as sales of psychedelic mushrooms. The licensing agreement contemplates the development of a stand-alone Marley brand portfolio of functional and psychedelic micro-dosing mushroom products, formats, devices and promotional items. To honor the legacy of Bob Marley in Jamaica, Silo Wellness has pledged a percentage of product sales to be contributed towards a charitable organization to be mutually agreed upon between the Marley family and Silo, the details of which will be made public in a future announcement.

“We are incredibly excited to strike a long-term licensing agreement with the most iconic brand to ever emerge from Jamaica,” stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “There is deep respect for the legacy of Bob Marley, and we are honored to be entrusted as good stewards of a brand that stands for universal wellness and natural healing. We look forward to introducing a portfolio of quality branded products with instant name recognition and global visibility, enabling Silo to introduce what we intend to become the leading brand name in the functional and psychedelic mushroom category.”

Today’s announcement follows Silo Wellness’ previously announced closing of its reverse take-over transaction on March 1, 2021 (the “RTO”) and subsequent listing of the common shares of Silo Wellness on the Canadian Securities Exchange on March 5, 2021. Concurrently with the RTO, Silo Wellness completed an approximate C$5 million concurrent financing. Please refer to the press release of Silo Wellness dated March 1, 2021 for further details of the RTO and concurrent financing

Founded in 2018, Silo Wellness is a ‘spore-to-door’ vertically integrated company that soft launched its legal functional mushroom e-store with eight tincture formulations in two different size formats available for purchase at SiloReboot.com. In addition to an online presence, Silo Wellness is exploring a first-of-its-kind brick and mortar retail operation in Ocho Rios, Jamaica where mushrooms will be offered in micro-dosing products as well as functional and psilocybin-based psychedelic mushroom and truffle formats.

Silo Wellness has been an early mover in the functional and psychedelic mushroom space and has already announced its proof of concept of a patent-pending, micro-dosing nasal spray format that this new brand partnership could potentially include. The full line of functional mushroom products to be launched under the Marley brand will be announced in the near future along with a fully-integrated marketing and communications campaign, which will include targeted digital advertising, social media presence, brand public relations and lifestyle marketing initiatives.

Corporate Update

The Company also reports that Fred Leigh has resigned from the board of directors of the Company. The Company’s board of directors and management would like to express their gratitude to Mr. Leigh for his invaluable contributions since joining the Company, including navigating the Company through the RTO, and wish him all the best in his future endeavours.

ABOUT SILO WELLNESS
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since inception, Silo Wellness’ activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

ABOUT MARLEY MERCHANDISING LLC 

The Marley brand honors the timeless values of Bob Marley by uniting people around the world under the banner of One Love. Marley Merchandising, LLC, a wholly owned Marley family entity, owns, licenses and markets a portfolio of Marley consumer brands globally, including: House of Marley®, Marley Beverage Co®, Marley Natural®, Marley Kitchen®, Marley Coffee®, and Bob Marley®. For more information, visit bobmarley.com and @bobmarley on social media.

Further Information

For further information, please contact:

Media Relations:
Stuart Kirby, VP of Marketing and Communications
press@silowellness.com

Investor Relations:
David Gdanski
(604) 343-2724
IR@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the partnership with Marley and the multi-year license agreement, the creation of Marley branded functional mushroom and microdosing psychedelic products where permitted by law, the market for such products, the resignation of Fred Leigh and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

All information contained in this news release with respect to Marley and Silo Wellness was supplied by each party respectively for inclusion herein and each party has relied on the accuracy of such information without independent verification.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.